98%
921
2 minutes
20
Background: Noninvasive cardiac radioablation is reported to be effective and safe for the treatment of ventricular tachycardia (VT).
Objective: This study aimed to analyze the acute and long-term effects of VT radioablation.
Methods: Patients with intractable VT or premature ventricular contraction (PVC)-induced cardiomyopathy were included in this study and treated using a single-fraction 25-Gy dose of cardiac radioablation. To quantitatively analyze the acute response after treatment, continuous electrocardiography monitoring was performed from 24 hours before to 48 hours after irradiation and at the 1-month follow-up. Long-term clinical safety and efficacy were assessed 1-year follow-up.
Results: From 2019 to 2020, 6 patients were treated with radioablation for ischemic VT (n = 3), nonischemic VT (n = 2), or PVC-induced cardiomyopathy (n = 1). In the short-term assessment, the total burden of ventricular beats decreased by 49% within 24 hours after radioablation and further decreased by 70% at 1 month. The VT component decreased earlier and more dramatically than the PVC component (decreased by 91% and 57% at 1 month, respectively). In the long-term assessment, 5 patients showed complete (n = 3) or partial (n = 2) remission of ventricular arrhythmias. One patient showed recurrence at 10 months, which was successfully suppressed with medical treatment. The posttreatment PVC coupling interval was prolonged (+38 ms at 1 month). Ischemic VT burden decreased more markedly than nonischemic VT burden after radioablation.
Conclusion: In this small case series of 6 patients, without a comparison group, cardiac radioablation appeared to decrease the intractable VT burden. A therapeutic effect was apparent within 1-2 days after treatment but was variable by etiology of cardiomyopathy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975004 | PMC |
http://dx.doi.org/10.1016/j.hroo.2022.11.006 | DOI Listing |
Int J Comput Assist Radiol Surg
September 2025
Department of Rhythmology, University Heart Center Lübeck, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, Lübeck, 23652, Germany.
Purpose: Ultrasound (US) is commonly used to assess left ventricular motion for examination of heart function. In stereotactic arrhythmia radioablation (STAR) therapy, managing cardiorespiratory motion during radiation delivery requires representation of motion information in computed tomography (CT) coordinates. Similar to conventional US-guided navigation during surgical procedures, 3D US can provide real-time motion data of the radiation target that could be transferred to CT coordinates and then be accounted for by the radiation system.
View Article and Find Full Text PDFEur Heart J Case Rep
September 2025
Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain.
Background: Ventricular tachycardias (VTs) are a life-threatening complication of patients with end-stage left ventricular dysfunction, and are a frequent cause for considering advanced therapies. Their management in patients supported by a left ventricular assist device (LVAD) presents unique challenges, requiring a multidisciplinary approach to tailored strategies.
Case Summary: We present the case of a 70-year-old male with a history of VTs who underwent HeartMate 3 (Abbott, USA) implantation for advanced heart failure secondary to ischaemic cardiomyopathy and refractory VTs.
J Appl Clin Med Phys
September 2025
Radiation Oncology Unit, Clinical Department, CNAO Foundation, Pavia, Italy.
Background: Stereotactic arrhythmia radioablation (STAR) is an emerging, non-invasive treatment for refractory ventricular arrhythmias. The technology requires target motion management.
Purpose: We studied the integration of a novel ultrasound probe and holder for heart motion management into proton-beam STAR treatment plans.
Europace
August 2025
School of Medicine, College of Medicine, Chung Shan Medical University, No. 110, Section 1, Jianguo North Road, Taichung 402306, Taiwan.
Med Phys
August 2025
Medical Physics Unit, Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.
Background: Ventricular tachycardia is a life-threatening cardiac arrhythmia for which radiation therapy is an emerging therapeutic option. Electroanatomic maps (EAMs) are used to define clinical target volumes (CTVs) in cardiac radioablation (CRA) treatment planning. Treatment planning systems are unable to integrate EAM data, thus many different workflows have been developed to guide clinicians in CTV creation.
View Article and Find Full Text PDF